SK Chemicals acquires commercialization approval of world’s 2nd zoster vaccine ‘Sky Zoster’
A Korean pharmaceutical company is expected to widen options for patients using its excellent technology power in the world’s zoster vaccine market which has been monopolized by a global pharmaceutical company.
SK Chemicals announced on the 9th that ‘Sky Zoster Inj(project name: NBP608),’ the co...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.